NAMSA announced that it appointed Dr. Christophe Berthoux as its new CEO to take over for former president & CEO John Gorski.
Berthoux most recently served as CEO of Synexus Clinical Research Limited and is also currently acting as operating partner at ArchiMed, a private equity healthcare firm that acquired a majority stake in NAMSA in September 2020.
The transition will be made effective March 22, 2021. Gorski will relinquish day-to-day operations to focus on strategy while serving as vice chair of NAMSA’s board of directors, according to a news release.
“Although my desire is to step down as CEO after fully committing 15 years as its leader, my heart is with NAMSA and I will continue to be involved in a meaningful way,” Gorski said in the release. “Dr. Berthoux possesses the expertise and vision for NAMSA’s future goals, and has the talent and drive to lead us forward. I look forward to working more closely with our Board of Directors to provide support to Christophe as he builds upon NAMSA’s marketplace position as the CRO leader in the medical device industry.”
“I am thrilled to be joining NAMSA’s global team,” added Berthoux. “I believe NAMSA has a great business model and talented management team that uniquely positions it to capitalize on the dynamic medtech development environment. As the industry continues to look for trusted partners to enable the expansion of life-saving technologies, I believe NAMSA is leading the way in providing robust and proven development solutions for Sponsors across the globe.”
Part of the transition plan includes the appointment of Nadim Yared as NAMSA’s new board of directors chairman. Yared currently serves as president & CEO at CVRx. He also acts as chairman of the Medical Device Innovation Consortium and previously held the position of chairman at AdvaMed.
